Financière de Tubize S.A.
TUB
Rangering i aksjer
#1951
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
Aksjekurs
$238.53
Markedsverdi
$10.62B
Endring (1 dag)
17.74%
Endring (1 år)
-9.51%
Land
BE
Handel Financière de Tubize S.A. (TUB)
Kategori
Healthcare
Aksjeprishistorikk for Financière de Tubize S.A. (TUB)
Høyeste sluttskurs: $206.81 den 2026-10-01
Laveste sluttskurs: $2.36 den 1987-01-01
Laveste sluttskurs: $2.36 den 1987-01-01
Aksjeprishistorikk for Financière de Tubize S.A. fra 1987 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -1.58% |
| 2025 | 71.69% |
| 2024 | 89.17% |
| 2023 | 4.67% |
| 2022 | -24.92% |
| 2021 | -0.07% |
| 2020 | 38.99% |
| 2019 | -0.27% |
| 2018 | -5.64% |
| 2017 | 24.16% |
| 2016 | -18.59% |
| 2015 | 13.12% |
| 2014 | 6.33% |
| 2013 | 41.09% |
| 2012 | 41.21% |
| 2011 | 6.11% |
| 2010 | -18.32% |
| 2009 | 101.99% |
| 2008 | -60.68% |
| 2007 | -34.72% |
| 2006 | 41.02% |
| 2005 | 10.45% |
| 2004 | 49.88% |
| 2003 | 30.83% |
| 2002 | -23.89% |
| 2001 | 12.33% |
| 2000 | -12.76% |
| 1999 | -43.88% |
| 1998 | 54.68% |
| 1997 | 79.87% |
| 1996 | 185.63% |
| 1995 | 55.94% |
| 1994 | 7.19% |
| 1993 | 19.56% |
| 1992 | -2.56% |
| 1991 | -0.97% |
| 1990 | -4.99% |
| 1989 | 97.32% |
| 1988 | 29.77% |
| 1987 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
